Welcome to LookChem.com Sign In|Join Free

CAS

  • or

6033-32-5

Post Buying Request

6033-32-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6033-32-5 Usage

Chemical Properties

L-6-HYDROXYNORLEUCINE is Off-White Solid

Uses

Different sources of media describe the Uses of 6033-32-5 differently. You can refer to the following data:
1. A key chiral intermediate used for synthesis of a vasopeptidase inhibitor.
2. L-6-HYDROXYNORLEUCINE is a key chiral intermediate used for synthesis of a vasopeptidase inhibitor

Check Digit Verification of cas no

The CAS Registry Mumber 6033-32-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,0,3 and 3 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 6033-32:
(6*6)+(5*0)+(4*3)+(3*3)+(2*3)+(1*2)=65
65 % 10 = 5
So 6033-32-5 is a valid CAS Registry Number.

6033-32-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name L-6-Hydroxy Norleucine

1.2 Other means of identification

Product number -
Other names L-6-HYDROXYNORLEUCINE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6033-32-5 SDS

6033-32-5Relevant articles and documents

-

Bodanszky,M. et al.

, p. 1030 - 1035 (1978)

-

Nitrilases

-

Paragraph 0265-0268, (2015/09/22)

The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition, methods of designing new nitrilases and methods of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

-

Paragraph 0288, (2014/10/18)

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDMIA, and methods of increasing gamma globin gene expression in a human or animal subject are also provided for the treatment diseases such as sickle cell disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 6033-32-5